Butonitazene

Butonitazene is a potent opioid analgesic drug related to etorphine and carfentanil, from the benzimidazole family of opioids. It was first reported in 1956 and subsequently marketed for human use under the brand name Moradol, but was withdrawn from market use due to problems with toxicity and dependence.

Pharmacology

Butonitazene is an opioid receptor agonist that is selective for the μ-opioid receptor. It has a high affinity for this receptor and is believed to act primarily by stimulating it, although it also has some affinity for the δ and κ receptors. The exact mechanism of action is not fully understood, but it is believed to involve inhibition of the reuptake of norepinephrine and serotonin, which can increase their levels in the brain and contribute to the drug's analgesic effects.

Medical Uses

Butonitazene was used for the relief of severe pain, such as that associated with cancer or severe injury. However, due to its high potency and potential for abuse and dependence, it is no longer used in human medicine.

Side Effects

The side effects of butonitazene are similar to those of other opioids and include respiratory depression, constipation, nausea, vomiting, dizziness, and sedation. In addition, it can cause severe dependence and withdrawal symptoms if used for extended periods.

Legal Status

Butonitazene is a Schedule I controlled substance in the United States, meaning it has a high potential for abuse and no accepted medical use. It is also controlled under similar laws in many other countries.

See Also

• Opioid
• Opioid receptor
• Benzimidazole

This article is a stub related to pharmacology. You can help WikiMD by expanding it!